ClinicalTrials.Veeva

Menu

The TearAD Study: Tear Biomarkers for Alzheimer's Disease (AD) Screening and Diagnosis

Maastricht University Medical Centre (MUMC) logo

Maastricht University Medical Centre (MUMC)

Status

Enrolling

Conditions

Alzheimer Disease

Treatments

Diagnostic Test: Tear Fluid collection (Schirmer's strip)
Diagnostic Test: Retinal imaging

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

The goal of this observational longitudinal study is to investigates whether tear fluid is a non-invasive source of biomarkers for Alzheimer's disease. The main aim of the study is to evaluate diagnostic accuracy measures (sensitivity and specificity) of tear and retinal biomarkers to discriminate individuals with and without neurodegeneration.

Tear fluid from participants will be collected non-invasively with Schirmer's strips, which is a small paper strip placed in the lower eye lid for a maximum of 5 minutes. Additionally, standard, ultra-wide field and cross-sectional retinal images will be obtained.

Enrollment

200 estimated patients

Sex

All

Ages

50+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria (healthy controls):

  • Available CSF, PET, CT or MRI data to evaluate the presence/absence of neurodegeneration (preferably within 1 year of inclusion in this study)
  • Absence of cognitive complaints or treatment and did not seek help for cognitive complaints in the past
  • MMSE score 26-30 at baseline
  • Age > 50 years
  • Available for follow-up (up to 24 months)
  • Written informed consent obtained and documented

Inclusion criteria (patients):

  • Available CSF, PET, CT or MRI data to evaluate the presence/absence of neurodegeneration (preferably within 1 year of inclusion in this study)
  • Available for follow-up (up to 24 months)
  • Written informed consent obtained and documented
  • Capable of giving informed consent themselves (MMSE score > 17/30)

Exclusion Criteria (all subjects):

  • Ocular conditions that could influence tear biochemical parameters (including eye infection, eye inflammation, eye surgery within the last 28 days or other acute eye conditions)
  • Neurological or systemic chronic conditions known to interfere with retinal thickness (e.g., glaucoma, diabetes mellitus)
  • Ocular conditions interfering with optical coherence tomography (OCT) quality/retinal thickness: e.g. severe cataract, age-related macular degeneration, and glaucoma

Trial design

200 participants in 2 patient groups

With Neurodegeneration
Description:
Includes patients with mild cognitive impairment and dementia
Treatment:
Diagnostic Test: Tear Fluid collection (Schirmer's strip)
Diagnostic Test: Retinal imaging
Without Neurodegeneration
Description:
Includes healthy controls and patients with subjective cognitive decline
Treatment:
Diagnostic Test: Tear Fluid collection (Schirmer's strip)
Diagnostic Test: Retinal imaging

Trial contacts and locations

2

Loading...

Central trial contact

Marlies Gijs, PhD; Nienke van de Sande, MSc

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems